Adaptimmune Ltd.
57c Milton Park
Abingdon
Oxfordshire
OX14 4RX
United Kingdom
Tel: +44-(0)-1235-438-642
Fax: +44-(0)-1235-438-607
Website: http://www.adaptimmune.com/
133 articles about Adaptimmune Ltd.
-
Adaptimmune Receives Orphan Drug Designation In The European Union For Its NY-ESO SPEAR T-Cell Therapy For Treatment Of Soft Tissue Sarcoma
7/26/2016
-
Adaptimmune To Present At The Bank of America Merrill Lynch 2016 Health Care Conference
5/3/2016
-
Adaptimmune Presents Corporate And Clinical Updates At Investor And Analyst Day
4/25/2016
-
Adaptimmune Announces FDA Acceptance Of IND Application For Affinity Enhanced T-Cell Therapy Targeting AFP In Liver Cancer
4/7/2016
-
FDA Grants Orphan Drug Designation To Adaptimmune’s T-Cell Therapy Targeting NY-ESO For Treatment Of Soft Tissue Sarcoma
3/30/2016
-
Adaptimmune Reports Financial Results For The Six-Month Period Ended December 31, 2015
3/17/2016
-
GlaxoSmithKline Bets Another $500 Million on Adaptimmune's Clinical Cancer Program
2/3/2016
-
Adaptimmune Expands T-Cell Engineering Expertise To Develop Affinity Enhanced T-Cell Therapies For Autoimmune Indications
1/7/2016
-
Adaptimmune Announces Initiation Of Study To Evaluate Its New Affinity Enhanced T-Cell Therapy Targeting MAGE-A10 In Patients With NSCLC, The Most Common Form Of Lung Cancer
12/17/2015
-
Adaptimmune And Universal Cells Announce Collaboration To Develop Allogeneic T-Cell Therapies
12/1/2015
-
Adaptimmune nitiates Phase I/II Trial Evaluating Its Affinity Enhanced T-Cell Therapy Targeting NY-ESO-1 In Patients With The Most Common Type Of Lung Cancer
11/25/2015
-
Adaptimmune To Participate In The Jefferies Autumn 2015 Global Healthcare Conference
11/12/2015
-
Adaptimmune Announces Data From Clinical Study Of NY-ESO Affinity Enhanced T-Cell Therapy In Synovial Sarcoma At The 2015 Annual Meeting Of The Society Of Immunotherapy For Cancer (SITC)
11/5/2015
-
Adaptimmune Announces Upcoming Data Presentation At The 2015 Annual Meeting Of The Society Of Immunotherapy For Cancer (SITC)
10/30/2015
-
Adaptimmune To Report Full Fiscal Year 2015 Financial Results On October 13, 2015
10/7/2015
-
Adaptimmune to Build New R&D Facility in the U.K.
10/6/2015
-
Adaptimmune To Participate In The Leerink Partners Inaugural Immuno-Oncology Roundtable
9/29/2015
-
Adaptimmune To Participate In Two Upcoming Investor Conferences
9/15/2015
-
Adaptimmune Announces Expansion Of Senior Team To Augment Clinical Expertise And Support Growth
9/9/2015
-
Adaptimmune To Participate In The 22nd Annual BioCentury 'Newsmakers In The Biotech Industry' Conference
9/3/2015